@article{75947814e8b045af9bb45e5976cbbb53,
title = "Association of Cancer Immunotherapy with Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis",
abstract = "Importance: Checkpoint inhibition in cancer immunotherapy related to T-cell-driven mechanisms of action associated with acute macular neuroretinopathy (AMN) and diffuse retinal venulitis, an adverse event not previously described, is reported here. Objective: To describe 2 patients who developed ophthalmologic events after treatment with the programmed death 1 axis inhibitor, atezolizumab. Design, Setting, and Participants: Retrospective review of 2 patients treated with atezolizumab for metastatic breast cancer and colon cancer, respectively, who presented with AMN and diffuse retinal venulitis conducted at 2 tertiary medical centers. Main Outcomes and Measures: Multimodal imaging including near infrared, optical coherence tomography, and fluorescein angiography were used to characterize retinal vascular abnormalities. Results: Based on optical coherence tomography and multimodal imaging findings, the clinical diagnosis of AMN associated with diffuse retinal venulitis was made in these 2 patients receiving atezolizumab. Conclusions and Relevance: While only 2 cases of patients receiving the programmed death ligand 1 inhibitor atezolizumab who experienced AMN and diffuse retinal venulitis are described here, these findings suggest that patients receiving programmed death 1 axis inhibitor therapies may need to be monitored for unexpected immune-related ocular toxicity including abnormalities of the microvasculature and large retinal vessels. Further studies might investigate the potential mechanisms of retinal vascular changes associated with these therapies.",
author = "Emens, {Leisha A.} and Davis, {S. Lindsey} and Oliver, {Scott C.N.} and Lieu, {Christopher H.} and Ashvini Reddy and Sharon Solomon and Lingmin He and Roland Morley and Marcella Fass{\`o} and Andrea Pirzkall and Hina Patel and Carol O'Hear and Daniela Ferrara",
note = "Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Emens reports grants and nonfinancial support from F. Hoffmann-La Roche AG during the conduct of the study; grants and nonfinancial support from Genetech Inc and Corvus Pharmaceuticals; grants and personal fees from AstraZeneca; grants from EMD Serono, MaxCyte, Merck, and Breast Cancer Research Foundation; personal fees from Syndax, Amgen, Medimmune, AbbVie, Gritstone Oncology, Peregrine Pharmaceuticals, Celgene, and eTHeRNA; nonfinancial support from Bristol-Myers Squibb; grants, personal fees, and nonfinancial support from Aduro Biotech; personal fees and nonfinancial support from Bayer, Replimune, Novartis, Vaccinex, and MacroGenics; and personal fees and other support from MolecuVax outside the submitted work and is a member of the Food and Drug Administration Advisory Committee on Cell Tissue and Gene Therapies (receive hourly compensation as special government employee), member of the Board of Directors for Society of Immunotherapy of Cancer (receive honoraria and travel), and steering committee member for the IMpassion130 trial and the KATE2 trial. Dr Davis reports clinical trial costs from Genentech Inc during the conduct of the study and travel support for investigator meeting for this study from Genentech Inc outside the submitted work. Dr Oliver reports grants from Roche/Genetech Inc outside the submitted work. Dr Morley reports being an employee of Genentech Inc and shareholder of F. Hoffmann-La Roche AG. Dr Fass{\`o} reports being an employee of Genentech Inc and shareholder of Aduro BioTech Inc. Dr Pirzkall reports being an employee of Genentech Inc and shareholder of F. Hoffmann-La Roche AG. Dr Patel reports being an employee of Genentech Inc and shareholder of F. Hoffmann-La Roche AG. Dr O{\textquoteright}Hear reports being an employee of Genentech Inc and shareholder of F. Hoffmann-La Roche AG. Dr Ferrara reports being an employee of Genentech Inc and shareholder of F. Hoffmann-La Roche AG. No other disclosures were reported. Publisher Copyright: {\textcopyright} 2018 American Medical Association. All rights reserved.",
year = "2019",
month = jan,
doi = "10.1001/jamaophthalmol.2018.5191",
language = "English (US)",
volume = "137",
pages = "96--100",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "1",
}